| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 41,946 | 18,661 | ||
| Restricted cash | 110 | 110 | ||
| Short-term investments | 57,150 | 104,284 | ||
| Other current assets | 4,229 | 4,889 | ||
| Total current assets | 103,435 | 127,944 | ||
| Operating lease right-of-use assets | 3,581 | 4,059 | ||
| Total, at cost | 14,490 | - | ||
| Accumulated depreciation | 12,455 | - | ||
| Property and equipment, net | 2,035 | 2,063 | ||
| Other assets | 713 | 640 | ||
| Total assets | 109,764 | 134,706 | ||
| Accounts payable | 4,651 | 3,937 | ||
| Accrued liabilities | 13,605 | 12,209 | ||
| Operating lease liabilities, current | 3,542 | 3,502 | ||
| Finance lease liabilities, current | 21 | 38 | ||
| Deferred revenue, current | 168 | 579 | ||
| Total current liabilities | 21,987 | 20,265 | ||
| Operating lease liabilities, net of current portion | 2,380 | 3,216 | ||
| Finance lease liabilities, net of current portion | 122 | 122 | ||
| 2023 common warrants liability | 13,396 | 9,191 | ||
| Long term liability | 46 | 46 | ||
| Total liabilities | 37,931 | 32,840 | ||
| Common stock, 0.0001 par value 115,800,000 shares and 20,800,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively 6,153,507 and 3,864,436 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 9 | 9 | ||
| Additional paid-in capital | 693,689 | 692,220 | ||
| Accumulated deficit | -622,320 | -590,783 | ||
| Accumulated other comprehensive income | 455 | 420 | ||
| Total stockholders' equity (deficit) | 71,833 | 101,866 | ||
| Total liabilities and stockholders' equity (deficit) | 109,764 | 134,706 | ||
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)